Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effects of elecoglipron compared with a placebo in adults with chronic kidney disease CKD, including those with and without type 2 diabetes mellitus T2DM. This Phase III, randomized, double-blind, placebo-controlled study includes participants who are receiving standard care treatments for CKD, including the SGLT2 inhibitor dapagliflozin. The study aims to determine whether elecoglipron can reduce the risk of kidney function decline, end-stage kidney disease, and mortality. Participants will be randomly assigned to receive either elecoglipron tablets or matching placebo tablets once daily. The study is multicenter and involves parallel groups. The treatment period and evaluation are event-driven and may last up to 4.5 years. Both study groups will continue their background therapies for CKD alongside the study medication or placebo. During the study, participants will be monitored regularly to assess kidney function, cardiovascular events, and overall health outcomes, including mortality. Researchers will measure sustained declines in estimated glomerular filtration rate eGFR, occurrence of end-stage kidney disease, cardiovascular death, heart failure hospitalizations, and other related outcomes. The study includes safety monitoring throughout the trial, which is expected to last until October 2030, with participant involvement potentially extending up to 4.5 years.
Actively Recruiting
Researchers are evaluating whether tenecteplase helps adults recover from an acute ischemic stroke when given more than 4.5 hours after the person was last seen well. This study focuses on people who had a stroke caused by a clot blocking a brain blood vessel and have imaging showing brain tissue that can still be saved. Participants are excluded if they are planned for a procedure to remove the clot. Participants are randomly placed into two groups. One group receives a single intravenous injection of tenecteplase, while the other group receives standard medical care. The trial compares these treatments to see if tenecteplase improves recovery when given later than the usual 4.5-hour window after stroke onset. Participants stay in the study for about three months, including roughly one week in the hospital. They undergo seven clinical visits or exams, with the last two likely done remotely from home. Doctors assess recovery using a scale that measures disability and dependence in daily life. They also monitor health and any side effects to compare outcomes between the two groups.
Actively Recruiting
Tuberculosis affecting the central nervous system CNS-TB remains a serious condition with high death rates and severe neurological problems despite current standard treatments. Researchers are studying whether adding doxycycline, a drug that may reduce harmful enzymes contributing to tissue damage, to standard anti-tuberculous therapy and corticosteroids can improve survival and reduce brain injury in CNS-TB patients. This is a Phase 2 randomized controlled trial focusing on outcomes at 8 weeks. Participants receive either doxycycline twice daily or a placebo, along with daily standard anti-tuberculosis drugs and corticosteroids tapered over 8 weeks. The anti-tuberculosis regimen includes multiple agents like rifampicin, isoniazid, ethambutol, and possibly others, adjusted for kidney function if needed. After 8 weeks, doxycycline or placebo is stopped, and patients continue their usual TB treatment under their physicians guidance. During the study, participants will have brain imaging and lumbar puncture at baseline and 8 weeks, with lab tests to measure specific enzymes and gene activity related to inflammation. Safety is monitored through liver tests and adverse event tracking. The main outcome is death or severe neurological disability measured by a standardized scale at 8 weeks. The study duration per participant is 8 weeks with close monitoring throughout.
Actively Recruiting
Researchers are evaluating whether combined supplementation with Channa striata extract and Curcuma domestica rhizome can improve nutritional status, reduce inflammation, and enhance quality of life in adults with active pulmonary tuberculosis receiving standard anti-tuberculosis treatment. Pulmonary tuberculosis often leads to malnutrition, ongoing inflammation, and lowered quality of life, all of which can delay recovery and worsen outcomes. The study aims to provide evidence for a safe, affordable, and locally available nutritional intervention to complement conventional tuberculosis care. Participants will receive either a combination of Channa striata 5 grams and Curcuma domestica rhizome 250 mg supplements or a placebo of maltodextrin. This randomized, double-blind, parallel study compares the effects of the combined supplements added to standard tuberculosis treatment. The treatment period lasts 4 weeks. During the study, participants inflammatory markers including interleukin-6 and C-reactive protein will be measured at the start and after 4 weeks. Nutritional status will be assessed through body weight, body mass index, muscle mass, and mid-upper arm circumference measurements. Quality of life will be evaluated using the EuroQol Five-Dimension Five-Level Questionnaire. Participants will be monitored throughout the 4-week period to track changes and safety.
Actively Recruiting
Patients with schizophrenia who are on long-term antipsychotic therapy often face chronic low-grade inflammation and metabolic issues, leading to worse physical health and higher cardiovascular risks. This trial is designed to study how Structured Medical Nutrition Therapy MNT affects the Systemic Inflammation Index SII, an inflammatory marker based on blood cell counts, in this population. The goal is to see if individualized nutrition support can better reduce inflammation compared to standard nutritional care. The trial compares two groups one receiving standard hospital diet according to institutional protocols and another receiving a modified diet tailored to each patients nutritional needs to improve dietary quality. The intervention period lasts 4 to 6 weeks, during which dietary changes and nutrition education are provided with regular monitoring. This approach aims to integrate nutritional therapy into the overall management of schizophrenia to address inflammation and metabolic health. Participants will be hospitalized adults aged 18 to 60 with schizophrenia, stable on antipsychotic medication for at least 4 weeks. Throughout the study, their Systemic Inflammation Index is measured at baseline and at the end of the intervention to evaluate changes. Other evaluations include monitoring dietary intake, health status, and laboratory tests. Safety and adherence are tracked during the hospital stay, and the total participation time covers the intervention period plus follow-up until the study ends.